Abnormal expression of MDM2 has been observed in various human cancers, potentially resulting from gene amplification, transcriptional regulation, and post‐translational modifications.[46] Small molecule inhibitors of MDM2 have been investigated as potential therapies for cancer.[47] At the protein level, the stability of MDM2 is regulated by other ubiquitin ligases, such as β‐Trcp, which directly binds to MDM2, leading to its degradation. This evidence concerns the gene MDM2 and cancer.